Waregem (Belgium) / Rotterdam (The Netherlands)[1], 15 December 2014 -The Extraordinary General Meeting of Shareholders of Arseus NV, held on 12 December 2014, approved the amendments to the Articles of Association and the change of the company name in Fagron NV.
The company’s listing on Euronext Brussels and Euronext Amsterdam will be changed to Fagron (new ticker symbol: FAGR) as of 1 January 2015.
The Meeting also approved the authorization of the Board of Management to acquire shares in the share capital of the company on behalf of the company up to 10% of issued share capital.
For further information:
Marieke Palstra
Director Investor Relations
+31 88 33 11 213
marieke.palstra@arseus.com
Arseus profile
Arseus is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Arseus consists of two divisions: Fagron and HL Technology. Fagron supplies pharmaceutical raw materials, equipment & supplies, concepts and pharmaceutical compounding to pharmacies and hospital pharmacies in 30 countries. Pharmaceutical compounding is an essential part of pharmaceutical care that enables pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron’s own R&D organization consists of 200 pharmacists who are working continually on developing new formulations for specific patients and patient groups. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals.
The Belgian company Arseus NV is located in Waregem and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
[1] This press release was sent out by Arseus NV and Arseus BV.
Please open the link below for the press release: